We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune... CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. Show more
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis PR Newswire LA JOLLA, Calif., April 24, 2024 Full target enrollment of 216 patients...
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., March 28, 2024 Enrollment in CARPO, Phase 2b trial of Auxora™ in acute...
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference PR Newswire LA JOLLA, Calif., March 13, 2024 Therapeutic...
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference PR Newswire LA JOLLA, Calif., Feb. 28...
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury PR Newswire LA JOLLA, Calif., Feb. 13, 2024 Phase 2 trial...
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire LA JOLLA, Calif., Feb. 7, 2024 LA JOLLA, Calif., Feb. 7, 2024 /PRNewswire/ -- CalciMedica...
CalciMedica Announces Private Placement of up to Approximately $55 Million PR Newswire LA JOLLA, Calif., Jan. 22, 2024 $20.4 million in upfront financing with the potential to receive up to an...
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., Nov. 9, 2023 Continued expansion of Phase 1/2 CRSPA study of...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.1 | 26.2529832936 | 4.19 | 5.8 | 4.01 | 21112 | 5.21934529 | CS |
| 4 | 1.38 | 35.2941176471 | 3.91 | 5.8 | 3.88 | 19894 | 4.54519264 | CS |
| 12 | -1.82 | -25.5977496484 | 7.11 | 7.76 | 3.3101 | 21336 | 4.48482727 | CS |
| 26 | 3.51 | 197.191011236 | 1.78 | 8.38 | 1.75 | 19139 | 4.27354922 | CS |
| 52 | 0.59 | 12.5531914894 | 4.7 | 8.59 | 1.75 | 18682 | 3.91766292 | CS |
| 156 | 0.02 | 0.379506641366 | 5.27 | 8.59 | 1.75 | 19557 | 4.05602035 | CS |
| 260 | 0.02 | 0.379506641366 | 5.27 | 8.59 | 1.75 | 19557 | 4.05602035 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
